Accordingly, KMT2C has been reported as a tumor repressor frequently altered in several types of cancers, including myeloid leukemia, colorectal cancer, medulloblastoma, pancreatic ductal adenocarcinoma, glioblastoma, and lung adenocarcinoma.28 Here, KMT2C is linked to neoplasm.